Page 5 - Nyse Ebs News Today

Cim Investment Management Inc. grew its stake in Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) by 100.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,482 shares of the biopharmaceutical company’s stock after purchasing an additional 4,741 shares during the […]

GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at...

Louisiana State Employees Retirement System boosted its holdings in Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) by 90.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,200 shares of the biopharmaceutical company’s stock after purchasing an additional 11,000 shares […]

Emergent BioSolutions (NYSE:EBS – Get Rating) had its price objective increased by Wells Fargo & Company from $37.00 to $40.00 in a research note published on Thursday morning, Marketbeat reports. Wells Fargo & Company currently has an equal weight rating on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on EBS. […]

Morgan Stanley lowered its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) by 36.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 295,584 shares of the biopharmaceutical company’s stock after selling 166,947 shares during the quarter. Morgan Stanley’s holdings in […]

Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45...

NEW YORK, June 4, 2021 /PRNewswire/ --

NEW YORK, April 29, 2021 /PRNewswire/ --

NEW YORK, April 24, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Emergent BioSolutions Inc. (NYSE: EBS) between July 6, 2020 through March 31, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 18, 2021. - Advertisement - SO WHAT: If you purchased Emerge...

HHS has increased Emergent’s task order by $23 million to purchase additional biologics manufacturing equipmentReaffirms 2021 financial...